An employee answers questions from the public near samples of a COVID-19 vaccine produced by Sinopharm subsidiary CNBG are displayed during a trade fair in Beijing on Sept. 6, 2020. CNBG has injected 350,000 people outside its clinical trials for COVID-19 vaccine, which have about 40,000 people enrolled. It's a highly unusual move that raises ethical and safety questions, as companies and governments worldwide race to develop a vaccine that will stop the spread of the new coronavirus. (AP Photo/Ng Han Guan)